Julia Sommer1, Andreas Seeling2, Harald Rupprecht3,4. 1. Department of Pharmacy, Klinikum Bayreuth GmbH, Bayreuth, Germany. julia.sommer@klinikum-bayreuth.de. 2. Institute of Pharmacy, Friedrich-Schiller-Universität Jena, Jena, Germany. 3. Department of Nephrology, Klinikum Bayreuth GmbH, Bayreuth, Germany. 4. KfH Dialysis Centre, Bayreuth, Germany.
Abstract
BACKGROUND AND PURPOSE: Chronic kidney disease (CKD) is associated with adverse drug events due to medication errors and the risks of polypharmacy. The aim of this study was to investigate whether multiple pharmacodynamic interactions are a significant problem in CKD patients to improve medication safety. METHODS: The discharge medication of 200 elderly patients with stage 3, 4 and 5/5D CKD was analysed in a retrospective observational study with respect to kidney-related medication errors and multiple pharmacodynamic interactions. The clinical relevance of the most common and hazardous multiple interactions was assessed by evaluating adverse events at the primary or the subsequent hospital stay. RESULTS: Findings showed that 29.5% of the study cohort were at risk of QTc-interval prolongation in association with their medication combinations and half of them exhibited QTc-interval prolongation. The QTc interval was extended among all patients receiving a combination of two or more drugs with 'known' risk of Torsades de pointes. Amiodarone, citalopram and ciprofloxacin turned out to be the most hazardous drugs in this context. Eight percent of the patient population received a regimen of 4-6 potassium-enhancing drugs during their hospital stay, which was not de-escalated in 75.0% in the ambulatory setting. Despite close monitoring in the clinical setting, 37.5% of these patients developed hyperkalaemic episodes during their primary stay and 66.7% during rehospitalization. Of the study cohort, 8.5% received a combination of three drugs with antithrombotic or antiplatelet effects. Of these, 64.7% developed haemorrhagic events with two of them proving fatal. CONCLUSION: Multiple pharmacodynamic interactions related to QTc prolongation, hyperkalaemia and haemorrhage are frequently associated with a negative outcome in older adults with CKD and often require recurrent medical treatment or rehospitalization.
BACKGROUND AND PURPOSE:Chronic kidney disease (CKD) is associated with adverse drug events due to medication errors and the risks of polypharmacy. The aim of this study was to investigate whether multiple pharmacodynamic interactions are a significant problem in CKDpatients to improve medication safety. METHODS: The discharge medication of 200 elderly patients with stage 3, 4 and 5/5D CKD was analysed in a retrospective observational study with respect to kidney-related medication errors and multiple pharmacodynamic interactions. The clinical relevance of the most common and hazardous multiple interactions was assessed by evaluating adverse events at the primary or the subsequent hospital stay. RESULTS: Findings showed that 29.5% of the study cohort were at risk of QTc-interval prolongation in association with their medication combinations and half of them exhibited QTc-interval prolongation. The QTc interval was extended among all patients receiving a combination of two or more drugs with 'known' risk of Torsades de pointes. Amiodarone, citalopram and ciprofloxacin turned out to be the most hazardous drugs in this context. Eight percent of the patient population received a regimen of 4-6 potassium-enhancing drugs during their hospital stay, which was not de-escalated in 75.0% in the ambulatory setting. Despite close monitoring in the clinical setting, 37.5% of these patients developed hyperkalaemic episodes during their primary stay and 66.7% during rehospitalization. Of the study cohort, 8.5% received a combination of three drugs with antithrombotic or antiplatelet effects. Of these, 64.7% developed haemorrhagic events with two of them proving fatal. CONCLUSION: Multiple pharmacodynamic interactions related to QTc prolongation, hyperkalaemia and haemorrhage are frequently associated with a negative outcome in older adults with CKD and often require recurrent medical treatment or rehospitalization.
Authors: Magdalene M Assimon; Patrick H Pun; Sana M Al-Khatib; M Alan Brookhart; Bradley N Gaynes; Wolfgang C Winkelmayer; Jennifer E Flythe Journal: Pharmacoepidemiol Drug Saf Date: 2022-03-24 Impact factor: 2.732
Authors: Joanna Q Hudson; Rebecca Maxson; Erin F Barreto; Katherine Cho; Amanda J Condon; Elizabeth Goswami; Jean Moon; Bruce A Mueller; Thomas D Nolin; Heather Nyman; A Mary Vilay; Calvin J Meaney Journal: Kidney Med Date: 2022-06-25
Authors: Lea Jung-Poppe; Hagen Fabian Nicolaus; Anna Roggenhofer; Anna Altenbuchner; Harald Dormann; Barbara Pfistermeister; Renke Maas Journal: J Clin Med Date: 2022-09-01 Impact factor: 4.964
Authors: Ioannis N Anastopoulos; Chloe K Herczeg; Kasey N Davis; Atray C Dixit Journal: Int J Environ Res Public Health Date: 2021-03-05 Impact factor: 4.614
Authors: Inge R F van Berlo-van de Laar; Ilona Prins-Can; Aliesa A de Lange; Katja Taxis; Frank G A Jansman Journal: Pharmacol Res Perspect Date: 2021-08